Related Experiment Video
Updated: Feb 15, 2026

Laparoscopic Repair of Para-Esophageal Hernia Using Absorbable Biosynthetic Mesh
Published on: September 11, 2021
Antenatal Medical Therapies to Improve Lung Development in Congenital Diaphragmatic Hernia
Aidan Kashyap1,2, Philip DeKoninck1,2, Kelly Crossley1,2
1The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia.
Insights
Severe congenital diaphragmatic hernia (CDH) may benefit from antenatal therapies. This review explores animal research on novel treatments like sildenafil to improve lung development before birth, offering alternatives to surgery.
Area of Science:
- Medical research
- Developmental biology
- Surgical innovation
Background:
- Congenital diaphragmatic hernia (CDH) is a severe birth defect impacting lung and vascular development.
- Current postnatal management has limitations for severe CDH cases.
- Antenatal surgical intervention (FETO) improves survival but carries risks and limitations.
Purpose of the Study:
- To review animal research on antenatal medical therapies for CDH.
- To explore the clinical applications of these novel therapies.
- To focus on sildenafil as a potential treatment for antenatal CDH management.
Main Methods:
- Literature review of animal studies on antenatal CDH therapies.
- Analysis of research on pulmonary development stimulation.
- Evaluation of phosphodiesterase-5 inhibitors, specifically sildenafil.
Main Results:
- Animal research provides a foundation for novel antenatal medical therapies.
- Sildenafil shows promise in stimulating antenatal pulmonary development in preclinical models.
- Medical therapies offer potential alternatives or adjuncts to surgical interventions.
Conclusions:
- Antenatal medical therapies represent a promising future direction for severe CDH management.
- Sildenafil is a key focus for further investigation due to its potential to enhance lung development.
- Further research is needed to translate preclinical findings into effective clinical treatments for CDH.
Abstract:
Congenital diaphragmatic hernia (CDH) is a birth defect characterized by failed closure of the diaphragm, allowing abdominal viscera to herniate into the thoracic cavity and subsequently impair pulmonary and vascular development. Despite improving standardized postnatal management, there remains a population of severe CDH for whom postnatal care falls short. In these severe cases, antenatal surgical intervention (fetoscopic endoluminal tracheal occlusion [FETO]) may improve survival; however, FETO increases the risk of preterm delivery, is not widely offered, and still fails in half of cases. Antenatal medical therapies that stimulate antenatal pulmonary development are therefore interesting alternatives. By presenting the animal research underpinning novel antenatal medical therapies for CDH, and considering the applications of these therapies to clinical practice, this review will explore the future of antenatal CDH management with a focus on the phosphodiesterase-5 inhibitor sildenafil.
Related Concept Videos
Lung Capacity
Inhaled Medications
Gene Therapy
Sustainable Development
Group Therapy
Endocarditis III: Medical Management

